Search Result

Isoforms Recommended:	DYRK1

Results for "

DYRK1A

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (4) Autophagy (1) Casein Kinase (3) CDK (11) Cholinesterase (ChE) (1) DYRK (42) ERK (1) GSK-3 (5) Haspin Kinase (2) Kinesin (1) Microtubule/Tubulin (1) Monoamine Oxidase (1) Pim (1) Ribosomal S6 Kinase (RSK) (1) ROS Kinase (1) Small Interfering RNA (siRNA) (3)
By Research Areas:	Cancer (25) Cardiovascular Disease (2) Infection (1) Inflammation/Immunology (2) Metabolic Disease (6) Neurological Disease (18)

Inhibitors & Agonists

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-147066

Dyrk1A-IN-4	DYRK	Cancer
Dyrk1A-IN-4 (compound 48) is a potent and orally active *DYRK1A* and *DYRK2* inhibitor with IC₅₀s of 2 nM and 6 nM, respectively. Dyrk1A-IN-4 has anticancer effects ^[1].

HY-RS04094

DYRK1A Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
DYRK1A Human Pre-designed siRNA Set A contains three designed siRNAs for DYRK1A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

DYRK1A Human Pre-designed siRNA Set A DYRK1A Human Pre-designed siRNA Set A

HY-RS04095

Dyrk1a Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Dyrk1a Mouse Pre-designed siRNA Set A contains three designed siRNAs for Dyrk1a gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Dyrk1a Mouse Pre-designed siRNA Set A Dyrk1a Mouse Pre-designed siRNA Set A

HY-RS04096

Dyrk1a Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Dyrk1a Rat Pre-designed siRNA Set A contains three designed siRNAs for Dyrk1a gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Dyrk1a Rat Pre-designed siRNA Set A Dyrk1a Rat Pre-designed siRNA Set A

HY-162107

Dyrk1A-IN-6	DYRK	Neurological Disease
Dyrk1A-IN-6 (compound 7cc) is an EGCG-like non-competitive inhibitor of *DYRK1A. Dyrk1*A-IN-6 can be used to alleviate cognitive defects in Down syndrome models ^[1].

HY-157995

Dyrk1A-IN-7	DYRK	Metabolic Disease Inflammation/Immunology Cancer
Dyrk1a-in-7 (Compound 29) is a selective *DYRK1A* kinase inhibitor, and has good kinase selectivity for CLK1 kinase. The IC₅₀ value of DYRK1A is 28 nM. For CLK2, K_d is 17.5 nM. Dyrk1a-in-7 can be used in the research of cancer, type Ⅱ diabetes and neurological diseases ^[1].

HY-146221

Dyrk1A-IN-5	DYRK	Neurological Disease
Dyrk1A-IN-5 (compound 5j) is a potent and selective *DYRK1A* inhibitor, with an IC₅₀ of 6 nM. Dyrk1A-IN-5 dose-dependently reduces the phosphorylation of Thr434 in SF3B1, with an IC₅₀ of 0.5 μM. Dyrk1A-IN-5 inhibits phosphorylation of tau at Thr212, with an IC₅₀ of 2.1 μM. Dyrk1A-IN-5 can be used for Down syndrome research ^[1].

HY-147760

Dyrk1A-IN-2	DYRK	Metabolic Disease
Dyrk1A-IN-2 (Compound 63) is a *DYRK1A* inhibitor with an EC₅₀ of 37 nM. Dyrk1A-IN-2 exhibits highly potent human β-cell replication-promoting activity and low cytotoxicity ^[1].

HY-139830

Dyrk1A-IN-1

DYRK Neurological Disease

Dyrk1A-IN-1 is a triple inhibitor of Dyrk1A kinase activity (IC₅₀ = 119 nM) and the aggregation of tau and α-syn oligomers.

Dyrk1A-IN-1	DYRK	Neurological Disease
Dyrk1A-IN-1 is a triple inhibitor of Dyrk1A kinase activity (IC₅₀ = 119 nM) and the aggregation of tau and α-syn oligomers.

HY-147060

Dyrk1A-IN-3	DYRK	Neurological Disease
Dyrk1A-IN-3 (Compound 8b), a highly selective dual-specificity tyrosine-regulated kinase 1A (DYRK1A) inhibitor, maintains high levels of DYRK1A binding affinity (IC₅₀=76 nM). Dyrk1A-IN-3 can be used for the research of neurodegenerative disorders such as Alzheimer’s Disease, Huntington’s Disease, and Parkinson’s Disease ^[1].

HY-146337

Dyrk1A/B-IN-1	DYRK	Cancer
Dyrk1A/B-IN-1 (compound 3n) is a potent, selective and cell-permeable *DYRK1A* and *DYRK1B* inhibitor with K_is of 67.8 nM and 237.9 nM, and IC₅₀s of 1.1 μM and 0.8 μM, respectively. Dyrk1A/B-IN-1 is not toxic to human cells. Dyrk1A/B-IN-1 can be used for researching DYRK1A and DYRK1B cellular functions and their role in pathologies ^[1].

HY-144695

Dyrk1A/α-synuclein-IN-1	DYRK	Neurological Disease
Dyrk1A/α-synuclein-IN-1 (Compound b1) is a dual *Dyrk1A* and α-synuclein aggregation inhibitor with IC₅₀ values of 177 nM and 10.5 µM, respectively. Dyrk1A/α-synuclein-IN-1 has high predictive CNS penetration and neuroprotective effect ^[1].

HY-144696

Dyrk1A/α-synuclein-IN-2	DYRK	Neurological Disease
Dyrk1A/α-synuclein-IN-2 (Compound b20) is a dual *Dyrk1A* and α-synuclein aggregation inhibitor with an IC₅₀ of 7.8 µM for α-synuclein. Dyrk1A/α-synuclein-IN-2 has high predictive CNS penetration and neuroprotective effect ^[1].

HY-122989

Aristolactam BIII	DYRK	Inflammation/Immunology
Aristolactam BIII is a potent *DYRK1A* inhibitor and inhibits the kinase activity of DYRK1A in vitro (IC₅₀= 9.67 nM. Aristolactam BIII rescues the proliferative defects of DYRK1A transgenic (TG) mouse-derived fibroblasts and neurological and phenotypic defects of DS-like Drosophila models ^[1].

HY-129449

AnnH31

Monoamine Oxidase DYRK Neurological Disease Cancer

AnnH31 is a Dyrk1A inhibitor (IC₅₀: 81 nM). AnnH31 also inhibits MAO-A with an IC₅₀ of 3.2 μM ^[1].

AnnH31	Monoamine Oxidase DYRK	Neurological Disease Cancer
AnnH31 is a *Dyrk1A* inhibitor (IC₅₀: 81 nM). AnnH31 also inhibits MAO-A with an IC₅₀ of 3.2 μM ^[1].

HY-146586

Haspin-IN-1	Haspin Kinase CDK DYRK	Cancer
Haspin-IN-1 (compound 2a) is a haspin inhibitor with an IC₅₀ of 119 nM. Haspin-IN-1 also inbibits *CLK1* and *DYRK1A* with IC₅₀s of 221 nM and 916.3 nM, respectively ^[1].

HY-146587

Haspin-IN-2	Haspin Kinase CDK DYRK	Cancer
Haspin-IN-2 (compound 4) is a potent and selective haspin inhibitor with an IC₅₀ of 50 nM. Haspin-IN-1 also inbibits *CLK1* and *DYRK1A* with IC₅₀s of 445 nM and 917 nM, respectively ^[1].

HY-144290

ARN25068

GSK-3 DYRK Neurological Disease

ARN25068 is a sub-micromolar inhibitor of the three protein kinases, GSK-3β, FYN and DYRK1A to tackle tau hyperphosphorylation ^[1].

ARN25068	GSK-3 DYRK	Neurological Disease
ARN25068 is a sub-micromolar inhibitor of the three protein kinases, GSK-3β, FYN and *DYRK1A* to tackle tau hyperphosphorylation ^[1].

HY-108476

INDY 2 Publications Verification	DYRK	Cancer
INDY is a potent and ATP-competitive *Dyrk1A* and *Dyrk1B* inhibitor with IC₅₀s of 0.24 μM and 0.23 μM, respectively. INDY binds in the ATP pocket of the enzyme and has a K_i value of 0.18 μM for Dyrk1A. INDY sharply reduces the self-renewal capacity of normal and tumorigenic cells in primary Glioblastoma (GBM) cell lines and neural progenitor cells ^[1] .

HY-12828A

KH-CB20	CDK DYRK	Infection Neurological Disease
KH-CB20, an E/Z mixture, is a potent and selective inhibitor of *CLK1* and the closely related isoform CLK4, with an IC₅₀ of 16.5 nM for *CLK1. KH-CB20 can also inhibit DYRK1A* (IC₅₀=57.8 nM) and CLK3 (IC₅₀=488 nM) ^[1].

HY-132308

DYRK1-IN-1 1 Publications Verification	DYRK	Neurological Disease
DYRK1-IN-1 is a highly selective and ligand-efficient *DYRK1A* inhibitor. DYRK1-IN-1 inhibits *DYRK1A* phosphorylation activity with an IC₅₀ value of 220 nM. DYRK1-IN-1 can be used for the research of central nervous system penetrant *DYRK1A* chemical probe ^[1].

HY-144614

JH-XVII-10	DYRK Apoptosis	Neurological Disease Cancer
JH-XVII-10 is a potent, selective and orally active *DYRK1A* and *DYRK1B* inhibitor with IC₅₀s of 3 nM and 5 nM for *DYRK1A* and *DYRK1B*, respectively. JH-XVII-10 shows antitumor efficacy in neck squamous cell carcinoma (HNSCC) cell lines ^[1].

HY-111379

EHT 5372	DYRK CDK GSK-3	Neurological Disease Metabolic Disease Cancer
EHT 5372 is a highly potent and selective inhibitor of *DYRK's* family kinases with IC₅₀s of 0.22, 0.28, 10.8, 93.2, 22.8, 88.8, 59.0, 7.44, and 221 nM for *DYRK1A, DYRK1B, DYRK2, DYRK*3, CLK1, CLK2, CLK4, GSK-3α, and GSK-3β, respectively ^[1] .

HY-144617

JH-XIV-68-3	DYRK	Cancer
JH-XIV-68-3 is a selective macrocyclic inhibitor of *DYRK1A/B. JH-XIV-68-3 displays selectivity for DYRK1A and close family member DYRK*1B in biochemical and cellular assays. JH-XIV-68-3 demonstrates antitumor efficacy in head and neck squamous cell carcinoma (HNSCC) cell lines ^[1].

HY-15569

NU6102	CDK	Cancer
NU6102 is a potent *CDK1* and CDK2 inhibitor with IC₅₀s of 9.5 nM and 5.4 nM for *CDK1/cyclinB* and CDK2/cyclinA3, respectively. NU6102 shows selectivity for *CDK1/CDK2* over CDK4 (IC₅₀ of 1.6 μM), DYRK1A (IC₅₀ of 0.9 μM), PDK1 (IC₅₀ of 0.8 μM) and ROCKII (IC₅₀ of 0.6 μM) ^[1] .

HY-12838

Mirk-IN-1

1 Publications Verification

DYRK1B/A-IN-1
DYRK Cancer

Mirk-IN-1 is a potent inhibitor of Dyrk1B(Mirk kianse) and Dyrk1A with IC50 of 68±48 nM and 22±8 nM respectively.

Mirk-IN-1 1 Publications Verification DYRK1B/A-IN-1	DYRK	Cancer
Mirk-IN-1 is a potent inhibitor of Dyrk1B(Mirk kianse) and Dyrk1A with IC50 of 68±48 nM and 22±8 nM respectively.

HY-142295

GNF2133	DYRK	Metabolic Disease
GNF2133 is a potent, selective and orally active *DYRK1A* inhibitor with IC₅₀s of 0.0062, >50 µM for DYRK1A and GSK3β, respectively. GNF2133 shows good proliferation potency and efficacy on rat and human primary β-cell. GNF2133 significantly improves glucose disposal capacity and increases insulin secretion. GNF2133 has the potential for the research of type 1 diabetes ^[1].

HY-142295A

GNF2133 hydrochloride	DYRK	Metabolic Disease
GNF2133 hydrochloride is a potent, selective and orally active *DYRK1A* inhibitor with IC₅₀s of 0.0062, >50 µM for DYRK1A and GSK3β, respectively. GNF2133 hydrochloride shows good proliferation potency and efficacy on rat and human primary β-cell. GNF2133 hydrochloride significantly improves glucose disposal capacity and increases insulin secretion. GNF2133 hydrochloride has the potential for the research of type 1 diabetes ^[1].

HY-135906

CK2/ERK8-IN-1	Casein Kinase ERK Pim DYRK Apoptosis	Cancer
CK2/ERK8-IN-1 is a dual casein kinase 2 (CK2) (K_i of 0.25 µM) and ERK8 (MAPK15, ERK7) inhibitor with IC₅₀s of 0.50 μM. CK2/ERK8-IN-1 also binds to *PIM1, HIPK2* (homeodomain-interacting protein kinase 2), and *DYRK1A* with K_is of 8.65 µM, 15.25 µM, and 11.9 µM, respectively. CK2/ERK8-IN-1 has pro-apoptotic efficacy ^[1].

HY-128759

DYRKs-IN-2	DYRK	Cancer
DYRKs-IN-2 (Example 132) is a potent *DYRKs* inhibitor with IC₅₀s of 30.6 nM and 12.8 nM for DYRK1B and DYRK1A, respectively. DYRKs-IN-2 has antitumor activity ^[1].

HY-110052

TBCA	Casein Kinase	Cancer
TBCA is a highly selective CK2 (casein kinase II) inhibitor with an IC₅₀ of 110 nM and a K_i of 77 nM. TBCA shows selectivity for CK2 over CK1, DYRK1A and a panel of 27 other kinases ^[1] .

HY-101298

Paprotrain 1 Publications Verification	Kinesin	Neurological Disease
Paprotrain is a cell-permeable inhibitor of the kinesin MKLP-2, inhibits the ATPase activity of MKLP-2 with an IC₅₀ of 1.35 μM and a K_i of 3.36 μM and shows a moderate inhibition activity on *DYRK1A* with an IC₅₀ of 5.5 μM.

HY-128758

DYRKs-IN-1	DYRK	Cancer
DYRKs-IN-1 is a potent *DYRKs* (Dual-specificity tyrosine-phosphorylation-regulated kinases) inhibitor with IC₅₀s of 5 nM and 8 nM for DYRK1A and DYRK1B, respectively. DYRKs-IN-1 has antitumor activity ^[1] .

HY-111380

EHT 1610 1 Publications Verification	DYRK	Neurological Disease
EHT 1610 is a potent inhibitor of *DYRK, with IC₅₀s* of 0.36 nM (DYRK1A), 0.59 nM (DYRK1B), respectively. EHT 1610 exhibits antileukemia effect, regulates cell cycle and induces cell apoptosis ^[1] ^- .

HY-128758A

DYRKs-IN-1 hydrochloride	DYRK	Cancer
DYRKs-IN-1 hydrochloride is a potent *DYRKs* (Dual-specificity tyrosine-phosphorylation-regulated kinases) inhibitor with IC₅₀s of 5 nM and 8 nM for DYRK1A and DYRK1B, respectively. DYRKs-IN-1 hydrochloride has antitumor activity ^[1] .

HY-77324S

4-(Trifluoromethyl)aniline-d4 4-Aminobenzotrifluoride-d₄	DYRK	Cancer
4-(Trifluoromethyl)aniline-d₄ is deuterium labeled 4-(Trifluoromethyl)aniline. 4-(Trifluoromethyl)aniline is a DYRK1A and DYRK1B kinase inhibitor with IC50s of 54.84 nM and 186.40 nM, respectively[1].

HY-105309

GSK-626616 3 Publications Verification	DYRK	Cardiovascular Disease
GSK-626616 is a potent, orally bioavailable inhibitor of *DYRK3* (IC₅₀=0.7 nM). GSK-626616 inhibits other members of the DYRK family (e.g., DYRK1A and DYRK2) with similar potency, which is a potential therapy for the treatment of anemia ^[1].

HY-15951

ML167 CID44968231; NCGC00188654	CDK DYRK	Cancer
ML167 is a highly selective Cdc2-like kinase 4 (Clk4) inhibitor with IC₅₀ of 136 nM, >10-fold selectivity for closely related kinases Clk1, Clk2, Clk3 and Dyrk1A/1B ^[1].

HY-N2892

Aristolactam A IIIa Aristololactam A IIIa; Sch 546909	DYRK	Cardiovascular Disease Cancer
Aristolactam A IIIa (Sch 546909) is an aristolactam-type alkaloid that can be isolated from Glycosmis chlorosperma. Aristolactam A IIIa is a *DYRK1A* Inhibitor. Aristolactam A IIIa inhibits platelet aggregation induced by arachidonic acid (AA), collagen and platelet-activating factor (PAF). Aristolactam A IIIa has strong cytotoxic effect on HeLa cells ^[1].

HY-129492

GNF4877 1 Publications Verification	DYRK GSK-3	Metabolic Disease
GNF4877 is a potent *DYRK1A* and GSK3β inhibitor with IC₅₀s of 6 nM and 16 nM, respectively, which leads to blockade of nuclear factor of activated T-cells (NFATc) nuclear export and increased β-cell proliferation (EC₅₀ of 0.66 μM for mouse β (R7T1) cells) ^[1].

HY-152183

FINDY	DYRK	Neurological Disease
FINDY is a folding intermediate-selective inhibitor of *DYRK1A. FINDY can inhibit Ser97 autophosphorylation with an IC₅₀* value of 35 μM. FINDY can be used for the research of neurological disorder ^[1]. FINDY is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-144826

ZDWX-25	GSK-3	Neurological Disease
ZDWX-25 is a highly potent GSK-3β and *DYRK1A* dual inhibitor with an IC₅₀ value of 71 nM for GSK-3β. ZDWX-25 possesses significant cytotoxic activities against SH-SY5Y and HL-7702 cells. ZDWX-25 can be used for researching alzheimer's disease ^[1].

HY-155723

Leucettinib-92	CDK DYRK	Others
Leucettinib-92 (compound 92) is an inhibitor of DYRK/CLK kinase, The IC₅₀s are 147 nM (CLK1), 39 nM (CLK2), 5.2 nM (CLK4), 0.8 μM (CLK3), 124 nM (DYRK1A), 204 nM (DYRK1B), 0.16 μM (DYRK2), respectively. 1.0 μM (DYRK3), 0.52 μM (DYRK4), 2.78 μM (GSK3) ^[1].

HY-101029

MBM-55
MBM-55 is a potent NIMA-related kinase 2 (Nek2) inhibitor with an IC₅₀ of 1 nM. MBM-55 shows a 20-fold or greater selectivity in most kinases with the exception of RSK1 (IC₅₀=5.4 nM) and DYRK1a (IC₅₀=6.5 nM). MBM-55 effectively inhibits the proliferation of cancer cells by inducing cell cycle arrest and apoptosis. MBM-55 shows antitumor activities, and no obvious toxicity to mice ^[1].

HY-149262

CLK1-IN-3	CDK DYRK Autophagy	Cancer
CLK1-IN-3 (compound 10ad) is a potent and selective *Clk1* inhibitor, with an IC₅₀ of 5 nM and over 300-fold selectivity for *Dyrk1A. CLK1-IN-3 also shows a relatively potent inhibition against Clk2* and Clk4, with IC₅₀ values of 42 and 108 nM, respectively. CLK1-IN-3 potently induces autophagy in vitro. CLK1-IN-3 can be used for acute liver injury (ALI) research ^[1].

HY-156816

ON 108600	Casein Kinase DYRK	Cancer
ON 108600 is a inhibitor for CK2 (Casein Kinase2)/TNIK/DYRK1 , with the IC₅₀s for *DYRK1A/DYRK*B, DYRK2, CK2α1/CK2α2, and TNIK of 0.016 μm/0.007 μM, 0.028 μM, 0.05 μM/0.005 μM, and 0.005 μM, respectively. ON 108600 has antitumor activity ^[1].

HY-101029A

MBM-55S	Ribosomal S6 Kinase (RSK) DYRK Apoptosis	Cancer
MBM-55S is a potent NIMA-related kinase 2 (Nek2) inhibitor with an IC₅₀ of 1 nM. MBM-55S shows a 20-fold or greater selectivity in most kinases with the exception of RSK1 (IC₅₀=5.4 nM) and DYRK1a (IC₅₀=6.5 nM). MBM-55S effectively inhibits the proliferation of cancer cells by inducing cell cycle arrest and apoptosis. MBM-55S shows antitumor activities, and no obvious toxicity to mice ^[1].

HY-117049

Leucettine L41	CDK DYRK	Neurological Disease
Leucettine L41 is a potent inhibitor of *dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A), DYRK2, CDC-like kinase 1 (CLK1), and CLK3* (IC₅₀s = 0.04, 0.035, 0.015, and 4.5 µM, respectively) ^[1]. Leucettine L41 prevents lipid peroxidation and the accumulation of reactive oxygen species (ROS) induced by Aβ_25-35 in the hippocampus in a mouse model of Alzheimer’s disease-like toxicity. Leucettine L41 also prevents memory deficits induced by Aβ_25-35 in the same model .

HY-112296

T025 2 Publications Verification	CDK Apoptosis DYRK	Cancer
T025 is an orally active and highly potent inhibitor of Cdc2-like kinase (CLKs), with K_d values of 4.8, 0.096, 6.5, 0.61, 0.074, 1.5 and 32 nM for CLK1, CLK2, CLK3, CLK4, DYRK1A, DYRK1B and DYRK2, respectively. T025 induces caspase-3/7-mediated cell apoptosis. T025 reduces CLK-dependent phosphorylation. T025 exerts anti-proliferative activities in both hematological and solid cancer cell lines (IC₅₀ values: 30-300 nM). T025 has an anti-tumor efficiency, mainly for MYC-driven disease research ^[1].

HY-150537

AChE/GSK-3β-IN-1	Cholinesterase (ChE) GSK-3 Microtubule/Tubulin ROS Kinase	Neurological Disease
AChE/GSK-3β-IN-1 (compound GT15) is a potent, dual AChE/GSK-3β inhibitor with IC₅₀ values of 1.2, 149.8 and 22.4 nM for hAChE , hBChE and hGSK-3β, respectively. AChE/GSK-3β-IN-1 penetrates the blood-brain barrier (BBB). AChE/GSK-3β-IN-1 has high kinase selectivity profiles for the CMGC kinase family. AChE/GSK-3β-IN-1 occupies the ATP binding site of DYRK1A. AChE/GSK-3β-IN-1 inhibits ROS expression and reduces oxidative stress. AChE/GSK-3β-IN-1 can be used for Alzheimer’s disease research ^[1].

Species:	Human (2)
Tag:	His (1) Tag Free (1)
Source:	E. coli (2)

Cat. No.	Compare	Product Name	Species	Source

HY-P701667

	DYRK1A Protein, Human DYRK1A; Dual specificity tyrosine-phosphorylation-regulated kinase 1A; Dual specificity YAK1-related kinase; HP86; Protein kinase minibrain homolog; MNBH; hMNB	Human	E. coli
	DYRK1A protein has dual serine/threonine and tyrosine kinase activities. DYRK1A Protein, Human is the recombinant human-derived DYRK1A protein, expressed by E. coli , with tag free. The total length of DYRK1A Protein, Human is 359 a.a., .

HY-P701668

	DYRK1A Protein, Human (His) DYRK1A; Dual specificity tyrosine-phosphorylation-regulated kinase 1A; Dual specificity YAK1-related kinase; HP86; Protein kinase minibrain homolog; MNBH; hMNB	Human	E. coli
	DYRK1A protein has dual serine/threonine and tyrosine kinase activities. DYRK1A Protein, Human (His) is the recombinant human-derived DYRK1A protein, expressed by E. coli , with N-6*His labeled tag. The total length of DYRK1A Protein, Human (His) is 359 a.a., .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks